Galderma (SWX:GALD), the pure-play dermatology category leader, announced today results from its new phase IIIb RELAX clinical trial demonstrating the rapid onset and the long-lasting duration of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback